風疹:治療薬開発パイプライン分析

Global Markets Directが発行した調査報告書(GMDHC9903IDB)
◆英語タイトル:Rubella (German Measles) - Pipeline Review, H2 2017
◆商品コード:GMDHC9903IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2017年11月14日
◆ページ数:33
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における風疹の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・風疹の概要
・風疹治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・風疹パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・風疹治療薬開発に取り組んでいる企業:企業別製品パイプライン
・風疹治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Rubella (German Measles) – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Rubella (German Measles) – Pipeline Review, H2 2017, provides an overview of the Rubella (German Measles) (Infectious Disease) pipeline landscape.

Rubella also known as the German measles is an acute, contagious viral infection. The rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Symptoms include fever, headache, stuffy or runny nose, inflamed, red eyes, aching joints and enlarged, tender lymph nodes at the base of the skull, the back of the neck and behind the ears.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Rubella (German Measles) – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Rubella (German Measles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rubella (German Measles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 1, 1, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Rubella (German Measles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rubella (German Measles) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Rubella (German Measles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rubella (German Measles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rubella (German Measles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rubella (German Measles) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rubella (German Measles) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rubella (German Measles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Rubella (German Measles) – Overview 6
Rubella (German Measles) – Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 11
Rubella (German Measles) – Therapeutics Assessment 12
Assessment by Route of Administration 12
Assessment by Molecule Type 14
Rubella (German Measles) – Companies Involved in Therapeutics Development 16
Beijing Minhai Biotechnology Co Ltd 16
Biological E Ltd 16
Cadila Healthcare Ltd 16
Daiichi Sankyo Co Ltd 17
GlaxoSmithKline Plc 17
Indian Immunologicals Ltd 18
Sinovac Biotech Ltd 18
Rubella (German Measles) – Drug Profiles 19
(measles + mumps + rubella + varicella) vaccine – Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
(measles + mumps + rubella) vaccine – Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
(measles + mumps + rubella) vaccine – Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
(measles + mumps + rubella) vaccine – Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
(measles + rubella + varicella) vaccine – Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
(measles + rubella) vaccine – Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
(measles + rubella) vaccine – Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
(measles + rubella) vaccine – Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
(measles + rubella) vaccine – Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine – Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
rubella vaccine – Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
VN-0102 – Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Rubella (German Measles) – Dormant Projects 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33

List of Tables
Number of Products under Development for Rubella (German Measles), H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products under Development by Universities/Institutes, H2 2017 9
Products under Development by Companies, H2 2017 10
Products under Development by Universities/Institutes, H2 2017 11
Number of Products by Stage and Route of Administration, H2 2017 13
Number of Products by Stage and Molecule Type, H2 2017 15
Rubella (German Measles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017 16
Rubella (German Measles) - Pipeline by Biological E Ltd, H2 2017 16
Rubella (German Measles) - Pipeline by Cadila Healthcare Ltd, H2 2017 17
Rubella (German Measles) - Pipeline by Daiichi Sankyo Co Ltd, H2 2017 17
Rubella (German Measles) - Pipeline by GlaxoSmithKline Plc, H2 2017 18
Rubella (German Measles) - Pipeline by Indian Immunologicals Ltd, H2 2017 18
Rubella (German Measles) - Pipeline by Sinovac Biotech Ltd, H2 2017 18
Rubella (German Measles) - Dormant Projects, H2 2017 31

List of Figures
Number of Products under Development for Rubella (German Measles), H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products by Routes of Administration, H2 2017 12
Number of Products by Stage and Routes of Administration, H2 2017 12
Number of Products by Molecule Types, H2 2017 14
Number of Products by Stage and Molecule Types, H2 2017 14

【レポートのキーワード】

風疹

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 風疹:治療薬開発パイプライン分析(Rubella (German Measles) - Pipeline Review, H2 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆